

IncellDx Signs Deal with CureHealth Diagnostics to Offer New HPV Technology in India

MENLO PARK - June 21, 2013, IncellDx announced today that it has reached an agreement to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in India.

The agreement with CureHealth Diagnostics of New Delhi increases IncellDx's presence in the India subcontinent and Middle East, the company said.

This test is based upon IncellDx's advanced molecular diagnostic technology for quantifying specific biomarkers and identifying cellular morphometric changes that have been associated with an increased risk of progression to cervical cancer, and will serve as a significant resource to physicians and hospitals managing diseases associated with women's health. CureHealth will be the first reference laboratory in India to offer this test.

Measuring the potential oncogenic activity of the human papillomavirus (HPV) in infected cervical cells, this novel test functions by detecting and quantifying the expression of viral oncogenes responsible for triggering progression, resulting in a higher specificity that existing tests lack. Specificity of a clinical test procedure determines the ability of a test procedure to detect no disease in a population of healthy, non-diseased people; meaning thereby no false positive results.

"IncellDx technology utilizes a flow-cytometry based method that can be used to identify the overexpression of HPV-encoded oncogenes, offering a better indicator of persistent HPV infections than can be accomplished by identifying the presence of free, un-reactive or harmless DNA infection alone," said Dr. Dinesh Gupta, PhD., Laboratory Director of CureHealth. "This addition to our growing line of molecular diagnostic tests for women's health (cervical cancer, breast cancer and sexually transmittable diseases) underscores our expanding specialization in advanced clinical and diagnostic testing. We intend to use this test initially for patients who have been seen carrying primary lesions by standard techniques such as VIA/ VILI with or without Pap test or with unclear colposcopic findings."

Bruce K. Patterson MD, founder and CEO of IncellDx, commented "The high level of specificity our technology produces has a significant, positive economic impact on healthcare delivery costs by rationalising the number of unnecessary colposcopy directed biopsies. We are excited that our partnership with CureHealth Diagnostics will expand our global reach as well as provide better healthcare outcomes for women in India and the subcontinent countries."

About IncellDx, Inc.

IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.

Contact: Eric Hass
IncellDx, Inc.
(T) +1.650.777.7630